Chinese Medical Doctor Association Pharmacoeconomics Chapter
Annual Report
2009

TO:
Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
3100 Princeton Pike, Suite 3E
Lawrenceville, NJ 08648 USA

PREPARED BY:
Dr. Ming Tang, Executive Director
Chinese Medical Doctor Association Pharmacoeconomics Professional Committee
(ISPOR Chinese MDA-PE Chapter)
Chinese Medical Doctor Association
Room 1802, A Tower Junfenghuating
No.69 Beichen West Road, Chaoyang District, Beijing, P.R. China
Email: pe@cmda.net; ming_tang_us@yahoo.com

Background:
The Chinese (MDA-PE Chapter) was accepted in January 2006. The Chapter has 50 members.

Current President is Dr. Shanlian Hu, MD, MSc, Professor, School of Public Health
Fudan University, Shanghai, P. R. China, and Director-General of Chinese Medical Doctor
Association Pharmacoeconomics Professional Committee.

The Chapter work of 2009 has accomplished greatly on several major aspects. The mission has been
carried on to promote the development and application of PE in China. Significant development
made in membership recruitment from 19 in 2008 to 50 in 2009 by inviting key leaders involving in
PE research projects. 8 PE evaluation research projects have been completed and 3 are undergoing
and will be accomplished by April 2010. The research papers will be published in the special PE
issue of Chinese Journal of Pharmacist. National continuous education of PE program has been
approved by MOH, and major cities such as Beijing, Shanghai, Guangzhou, Chengdu, and etc will be
CMDA-PE’s footholds. The program not only provides trainings to doctors and experts in different
clinical disciplines, but also collaborates with China HIRA to compile guidelines of PE application in
basic health insurance.

For more information, please visit http://www.ispor.org/regional_chapters/China/index.asp.
Enclosure: Chinese MDA-PE Chapter Annual Report 2009

**Chinese MDA-PE Chapter Annual Report 2009**  
*(Chinese Medical Doctor Association Pharmacoeconomics Committee)*

**Accomplishments Made in 2009**

<table>
<thead>
<tr>
<th>Accomplishments</th>
<th>Major Aspects</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Mission &amp; membership development</td>
<td>Promote the development and application of Pharmacoeconomics in China, not only applying PE knowledge in different clinical disciplines, but also developing memberships within clinician. ISPOR CMDA-PE chapter invites key opinion leaders involving in the disease intervention through PE research projects. 50 membership was developed in 2009</td>
</tr>
<tr>
<td>2 Research &amp; professional growth</td>
<td>Studied on drug utilization and market situation of diseases of tumor, skin, eye, digestive, diabetes and mental disorders’ drugs, such as oryz-asprgillus enzyme and pancreatin, muco-polysaccharide polysulfate, atomoxetine hydrochloride and new-type insulin, etc. Number of Pharmacoeconomic evaluation conducted is 11 projects. As of the end of 2009, 8 research projects have been completed. The remaining three projects will be accomplished by April 2010. The research papers will be published in the special PE issue of Chinese Journal of Pharmacist.</td>
</tr>
<tr>
<td>3 Publication &amp; Influences</td>
<td>Collaborated with Chinese Journal of Pharmacist has established a Pharmacoeconomics series which is usually published the research and application of Pharmacoeconomics papers. The series are not only reporting the research findings by ISPOR CMDA-PE Chapter, but also recalling clinical experts, health statisticians and pharmacologists to contribute their papers. 15 PE research papers have been published in Chinese Journal of Pharmacist, such as some post-marketing pharmacoeconomic evaluation and cost-minimization analysis of traditional medicines, eye drops and some drugs for treatment of thoracic carcinoma.</td>
</tr>
</tbody>
</table>
4. Education & Training

Department of Health Education, MOH, issued the requirement of continuous education and set a target called “Developing 100 programs in recent 10 years”. Two training courses conducted by ISPOR CMDA-PE Chapter have been approved by MOH. One is “the Application of Pharmacoeconomic Evaluation Research in Clinical Practice” (Approval number: 2010-13-01-051, 5 credits). The other is “the Management Model of Rational Use of Drug in Rural Cooperative Medical Scheme in China”.

ISPOR CMDA-PE Chapter will use the PE research findings as case studies. The program will plan to expand in Beijing, Shanghai, Guangzhou, Chengdu, etc. Those courses will train doctors in different clinical disciplines so as to disseminate the knowledge and skills of Pharmacoeconomics and Outcomes Research and the capacity building.

5. Contribution to Insurance Policy making

Based on the review of all formularies and guidelines of rational use of drug in China, now ISPOR CMDA-PE Chapter has been working on the guidelines of clinical use of pharmaceuticals, which will be applied both in medical society and health insurance society as a tool kit. It is expected that the first version will be published in 2010. According to the management of medical insurance, the guidelines will be renewed periodically.

6. Utilizing International experiences on PE Researches

Communicated with Analysis Group in USA. CMDA-PE chapter would like to learn their experience of using tools in the development of Pharmacoeconomics, which will adopt Chinese situation and use by related government sectors.
The Plan of 2010

<table>
<thead>
<tr>
<th></th>
<th>Further development of membership</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Expect to expand membership to 300 people in 2010.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Developing international exchange program</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.</td>
<td>Conduct international exchange program with University of Southern California and NICE (National Institute for Health and Clinical Excellence) in the United Kingdom in order to widen the view of Pharmacoeconomics research and its application from developed countries.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Great prospects in 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.</td>
<td>Confident in upgrading the program to a new stage that will make important contribution to the future health system reform in China.</td>
</tr>
</tbody>
</table>